Advanced Search

Pathophysiology of Chronic Kidney Disease (CKD) Evaluations

To view Evaluated Articles, you must have an active subscription (or trial) and be signed in.
If you have an active subscription (or trial), please sign in. If your access has expired, you can subscribe at $9.95 per month. If you think you should be able to access this content, please contact us.

Sign in | Free Trial | Subscribe | Recommend to Library

New to F1000? See the Top Rated article below for a free preview of one of our Evaluated Articles.

SECTION HEADS

  • Photo of Rajiv Agarwal

    Rajiv Agarwal

    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

  • Photo of David Basile

    David Basile

    Department of Cellular & Integrative Physiology, Indiana University, Indianapolis, IN, USA

Section Topics

  • » Anemia in CKD
  • » Calcium, phosphate, vitamin D, parathyroid hormone & metabolic bone disease in CKD
  • » Cardiovascular disease complicating CKD
  • » Clinical trials of interventions for slowing the progression of CKD
  • » Dyslipemia in CKD
  • » Glomerular & tubular adaptations to nephron loss
  • » Hypertension in CKD
  • » Inflammation & fibrosis in CKD
  • » Mechanisms underlying progression of CKD
  • » Novel treatments for CKD
  • » Nutrition in CKD
  • » Pathogenesis & treatment of diabetic nephropathy
  • » Proteinuria in CKD
  • » Renin-angiotensin-aldosterone system in CKD
  • » Sympathetic nervous system in CKD

LATEST EVALUATION

Podocyte abnormalities underlie many kidney diseases that result in chronic renal failure, but the mechanisms that govern podocyte renewal were unknown. This paper reports new knowledge that sheds light on the cellular processes that control...

Tak Mao Chan and Susan Yung, University of Hong Kong, Queen Mary Hospital, Hong Kong. F1000 Nephrology

6 Recommended

TOP RATED ARTICLE THIS WEEK [FREE TO VIEW]

6
Telmisartan Exerts Renoprotective Actions via Peroxisome Proliferator-Activated Receptor-γ/Hepatocyte Growth Factor Pathway Independent of Angiotensin II Type 1 Receptor Blockade.

Kusunoki H, Taniyama Y, Azuma J, Iekushi K, ..., Iwabayashi M, Okayama K, Rakugi H, Morishita R. Hypertension. 2012 Feb; 59(2):308-16

1 Evaluation, most recent by

Alejandro Chade, University of Mississippi Medical Center, USA. F1000 Nephrology

INDIVIDUALS

Get instant access to evaluations from over 10,000 experts in biology and medicine by taking a free trial or an individual subscription.

Get a FREE Trial Subscribe for $9.95 per month

Already have a subscription? Sign in for instant access. If you are signed in but are not able to view content, your access has expired. Please take out a subscription or recommend F1000 to your librarian.

RECOMMENDATIONS

Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.

Recommend to your Librarian

LIBRARIANS & INFORMATION MANAGERS

Get an extended free trial supporting clinicians and researchers at your academic or corporate institution.

Request an Institutional Trial

FREE ACCESS

Your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.

Faculty of 1000